{"id":"janagliflozin-plus-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Gastrointestinal disturbances (metformin-related)"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Polydipsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Janagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, promoting urinary glucose excretion independent of insulin. Metformin, a biguanide, decreases hepatic gluconeogenesis and enhances peripheral glucose uptake. Together, this combination provides complementary glucose-lowering effects through distinct mechanisms.","oneSentence":"Janagliflozin is an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption, combined with metformin which decreases hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:38.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03851432","phase":"PHASE3","title":"Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin","status":"UNKNOWN","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2019-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Janagliflozin plus metformin","genericName":"Janagliflozin plus metformin","companyName":"Sihuan Pharmaceutical Holdings Group Ltd.","companyId":"sihuan-pharmaceutical-holdings-group-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Janagliflozin is an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption, combined with metformin which decreases hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}